scholarly article | Q13442814 |
P356 | DOI | 10.4161/HV.7.9.15999 |
P8608 | Fatcat ID | release_bgoaaa7obbaahie5fcms5fwfjm |
P932 | PMC publication ID | 3225769 |
P698 | PubMed publication ID | 21892005 |
P5875 | ResearchGate publication ID | 51618391 |
P50 | author | Jacek Wysocki | Q11715678 |
Marek Spaczyński | Q107396894 | ||
P2093 | author name string | Achim Schneider | |
Tino F Schwarz | |||
Dominique Descamps | |||
Gregory Catteau | |||
Florence Thomas | |||
Andrzej Galaj | |||
Karin Schulze | |||
Sylviane M Poncelet | |||
P2860 | cites work | Immunosenescence and influenza vaccine efficacy | Q37600681 |
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. | Q40227526 | ||
Monophosphoryl lipid A as an adjuvant. Past experiences and new directions | Q40408110 | ||
Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature | Q43446049 | ||
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years | Q43452461 | ||
Persistence of specific antibodies after hepatitis B vaccination | Q43489279 | ||
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses | Q43782984 | ||
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials | Q44324590 | ||
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant | Q45403548 | ||
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 | ||
HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives | Q45734349 | ||
Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration | Q45759554 | ||
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc | Q51865830 | ||
Maintenance of serological memory by polyclonal activation of human memory B cells. | Q52008907 | ||
Humoral immunity due to long-lived plasma cells. | Q52040025 | ||
The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. | Q52945818 | ||
Human papillomavirus and cervical cancer | Q54023273 | ||
Are booster immunisations needed for lifelong hepatitis B immunity? | Q54226776 | ||
Hepatitis B vaccination: how long does protection last? | Q72586604 | ||
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity | Q73465852 | ||
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years | Q82674941 | ||
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial | Q83988269 | ||
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women | Q84579133 | ||
The causal relation between human papillomavirus and cervical cancer | Q24673148 | ||
Global cancer statistics, 2002 | Q27860562 | ||
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial | Q28236008 | ||
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 | ||
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years | Q28255234 | ||
Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix | Q28268292 | ||
Prevalence of HPV infection among females in the United States | Q28290509 | ||
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia | Q28296557 | ||
Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 | ||
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide | Q29617514 | ||
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. | Q30730983 | ||
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection | Q33698774 | ||
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas | Q33707499 | ||
In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection | Q34125906 | ||
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica | Q34557325 | ||
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only | Q34568949 | ||
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial | Q34580726 | ||
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis | Q34642665 | ||
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives | Q34655188 | ||
Hepatitis B vaccine -- do we need boosters? | Q35056955 | ||
Antigen dependent and independent mechanisms that sustain serum antibody levels | Q35134698 | ||
Hepatitis A booster vaccination: is there a need? | Q35548831 | ||
Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. | Q35854601 | ||
Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening | Q36459799 | ||
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. | Q36584350 | ||
Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis | Q36670753 | ||
Vaccination in the elderly: an immunological perspective | Q37084886 | ||
Age-related decline in immunity: implications for vaccine responsiveness | Q37150322 | ||
Immunobiology of HPV and HPV vaccines | Q37161653 | ||
P433 | issue | 9 | |
P921 | main subject | cervix uterine cancer | Q160105 |
P304 | page(s) | 958-965 | |
P577 | publication date | 2011-09-01 | |
P1433 | published in | Hum Vaccin | Q15755183 |
P1476 | title | Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years | |
P478 | volume | 7 |
Q41378317 | Acceptability of human papillomavirus vaccines among women older than 26 years |
Q34102466 | Alternative dosage schedules with HPV virus-like particle vaccines |
Q92867229 | An investigation into the role of chronic Schistosoma mansoni infection on Human Papillomavirus (HPV) vaccine induced protective responses |
Q37709718 | Does the HPV vaccination programme have implications for cervical screening programmes in the UK? |
Q36977720 | Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study |
Q34291136 | Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. |
Q36978399 | Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule |
Q28081156 | Long-term efficacy and safety of human papillomavirus vaccination |
Q35550810 | Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females |
Q35810353 | Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study |
Q30780649 | Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme |
Q38735932 | Predictors of Adults' Knowledge and Awareness of HPV, HPV-Associated Cancers, and the HPV Vaccine: Implications for Health Education |
Q38460201 | Present status of human papillomavirus vaccine development and implementation |
Q26749285 | Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline |
Q54217505 | Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. |
Q33162724 | Safety of human papillomavirus vaccines: a review. |
Q36978409 | Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination |
Q34733896 | Vulval cancer and HPV vaccination in recurrent disease |
Search more.